Floatz logo

Hyoscine

Scopolamine

Ruijin HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Scopolamine cohort.

Asset / SponsorPhaseRating
Compound Edaravone
Ruijin Hospital
Phase 2CCC
Bxcl501
Ruijin Hospital
Phase 2CCC
Atropine
Ruijin Hospital
Phase 2CCC

Same molecule, other indications

Hyoscine is also rated in:

Bariatric Surgery CandidateDormant
BB
Indicative ·
64 / 100
View asset →
Systemic Inflammatory Response SyndromeDormant
BB
Indicative ·
64 / 100
View asset →
Postoperative Pain, AcuteDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →